Status:

COMPLETED

Research Study to Investigate How a Study Medicine (NNC9204- 1177) Affects Blood Levels of Other Medicines in Healthy People

Lead Sponsor:

Novo Nordisk A/S

Conditions:

Healthy Volunteers

Overweight

Eligibility:

All Genders

18-60 years

Phase:

PHASE1

Brief Summary

The study looks at how the study medicine (NNC9204-1177) affects other medicines in the body. Participants will get the study medicine and 5 other medicines which have all been approved by the authori...

Eligibility Criteria

Inclusion

  • Male or female, aged 18-60 years (both inclusive) at the time of signing informed consent.
  • Body mass index (BMI) between 23.0 and 29.9 kg/m\^2 (both inclusive) at screening.
  • Considered to be generally healthy based on the medical history, physical examination, and the results of vital signs, electrocardiogram (ECG) and clinical laboratory tests performed during the screening visit, as judged by the investigator.

Exclusion

  • Female who is pregnant, breast-feeding or intends to become pregnant or is of child-bearing potential and not using a highly effective contraceptive method (intra-uterine device (IUD), vasectomised partner or sexual abstinence)
  • Any disorder, which in the investigator's opinion might jeopardise subject's safety or compliance with the protocol.
  • Use of prescription medicinal products or non-prescription drugs, except for IUDs, within 14 days prior to the day of screening.
  • Use of any herbal medicine known to interfere with the metabolic CYP pathways, such as Hypericum (St. John's Wort), ginseng, garlic, milk thistle, and echinaceae, within 14 days prior to the day of screening.

Key Trial Info

Start Date :

August 15 2019

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

January 2 2020

Estimated Enrollment :

45 Patients enrolled

Trial Details

Trial ID

NCT04059367

Start Date

August 15 2019

End Date

January 2 2020

Last Update

January 22 2020

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Novo Nordisk Investigational Site

San Antonio, Texas, United States, 78209